Relation between symptom duration before thrombolytic therapy and final myocardial infarct size

Area of Science:

• Cardiology
• Cardiovascular Medicine
• Interventional Cardiology

Background:

• Myocardial salvage is maximized with thrombolytic therapy within 4-6 hours of myocardial infarction symptom onset.
• The precise impact of early delays (within this window) on final infarct size remains unclear.
• This study quantifies the relationship between symptom duration and infarct size in patients treated within 6 hours.

Purpose of the Study:

• To determine the correlation between the time from symptom onset to thrombolytic therapy and the final myocardial infarct size.
• To analyze data from patients treated within six hours of acute myocardial infarction symptom onset.

Main Methods:

• Analysis of data from 432 patients in four prospective randomized trials of thrombolytic therapy.
• Estimation of myocardial area at risk using ECG criteria before treatment.
• Measurement of final infarct size using thallium-201 scintigraphy several weeks post-infarction.

Main Results:

• No significant difference in the initial area at risk for infarction based on symptom duration.
• Final infarct size was strongly dependent on the delay before thrombolytic therapy.
• Each 30-minute delay increased infarct size by 1% of the myocardium; treatment at 4-6 hours yielded results similar to no treatment.

Conclusions:

• Increasing symptom duration before thrombolytic therapy progressively reduces myocardial salvage.
• These findings underscore the critical importance of minimizing treatment delays for reperfusion therapy in acute myocardial infarction.
• Prompt initiation of therapy is essential for maximizing the benefit of thrombolytic treatment.